2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Why the study?
New evidence published since the 2019 ESC/EAS Guidelines could influence clinical practice in the management of dyslipidaemias and required updated recommendations.
Comparison
Updated recommendations for cardiovascular risk estimation and lipid-lowering therapies versus 2019 ESC/EAS Guidelines
Design
Focused Update of ESC/EAS clinical practice guidelines based on systematic literature review and expert consensus
Authors
Discussion
Loading...
Member takes
Implication
Revises lipid management for ACS, HIV, and statin-intolerant patients; extends 2019 ESC/EAS guidelines with post-2019 trial data.
Key Points
- To provide updated, evidence-based clinical recommendations for the management of dyslipidaemias and cardiovascular risk reduction following new trial data published since 2019.
- A joint Task Force from the ESC and EAS critically reviewed randomized controlled trials, systematic reviews, and meta-analyses published after the 2019 guidelines.
- The expert panel evaluated updated risk scores (SCORE2/SCORE2-OP) and trials evaluating non-statin lipid-lowering therapies across multiple distinct clinical cohorts.
- Evidence tables and consensus-based class and level-of-evidence grading systems were applied to formulate clinical practice recommendations.
- Bempedoic acid demonstrated significant cardiovascular event reduction in statin-intolerant patients, expanding non-statin pharmacological options.
- Immediate initiation of intensive combination lipid-lowering therapy during index hospitalization for acute coronary syndromes improved attainment of low-density lipoprotein cholesterol targets.
- Recommendations were revised or newly established for cardiovascular risk assessment using SCORE2, universal lifetime measurement of lipoprotein(a), statin therapy in people with HIV, and avoidance of unproven dietary supplements.
Structured PICO
P
Population
Persons without known cardiovascular disease, patients with acute coronary syndromes, familial hypercholesterolaemia, HIV, and cancer patients at high chemotherapy-related cardiovascular toxicity risk
I
Intervention
Cardiovascular risk estimation (SCORE2, SCORE2-OP) and lipid-lowering therapies (including new LDL-C lowering therapies, combination therapies during ACS hospitalization, and treatments for hypertriglyceridaemia)
The 2025 ESC/EAS Focused Update incorporates recent trial data to revise recommendations on cardiovascular risk estimation, novel lipid-lowering therapies, and specific patient populations like those with ACS, HIV, or cancer.
Cite This Study
Mach et al. (2025) conducted a review in Dyslipidaemia. Lipid-lowering therapies was evaluated. The 2025 ESC/EAS Focused Update provides revised recommendations for cardiovascular risk estimation, new LDL-C lowering therapies, and lipid management in specific populations.